Research & Education

Harmony Biosciences Holdings Fair Value: 63.7% Upside

2026-07-23 · fairvalue-calculator.com

By Dr. Peter Klein, BA · Founder

Harmony Biosciences Holdings Fair Value Analysis: 63.7% Upside to $60.3

Harmony Biosciences Holdings (HRMY) develops and commercializes therapies for rare neurological disorders, with its flagship product WAKIX (pitolisant) approved for excessive daytime sleepiness in narcolepsy. At the current price of $36.84, our comprehensive valuation framework places the stock’s fair value at $60.3, representing a compelling +63.7% upside. With a Quality Score of 66/100, the company earns an “undervalued” verdict from our models.

Business Overview and Recent Performance

Harmony’s core focus remains WAKIX, which continues to demonstrate strong demand. In Q2 2026 the company reported record net product revenue and reaffirmed full-year 2026 guidance of $1.0–$1.04 billion. Analysts have noted solid outperformance in the sleep-disorder market alongside ongoing pipeline efforts in rare diseases. Recent news also highlighted a CFO transition, which markets initially viewed as a neutral-to-positive development given operational continuity.

Why Our Model Sees Significant Undervaluation

Our fair-value estimate of $60.3 integrates 21 distinct valuation approaches, including discounted cash flow, multiples-based methods, and scenario analysis. The primary drivers are:

Strong top-line trajectory supported by WAKIX’s market penetration and expanding indications.
Attractive normalized P/E in the low teens that does not fully reflect projected earnings growth through 2028.
Pipeline optionality in sleep and rare-disease markets that adds asymmetric upside not fully priced in.

Analyst consensus price targets average around $42–$45, with some bullish calls reaching $55. Our model’s higher fair value reflects more optimistic yet data-supported assumptions on long-term revenue and margin expansion.

💡 Theory is good, numbers are better. Get the fair value of any stock worldwide in seconds. Try it free →

Key Valuation Drivers

Revenue growth from WAKIX remains the dominant driver, with forecasts pointing to continued double-digit expansion. Margin improvement as the product matures and potential new indications further support higher earnings power. The stock’s current valuation multiple appears compressed relative to peers in the specialty-pharma space, creating a margin-of-safety opportunity for long-term investors.

Ready to run your own scenarios? Use the free Fair Value Calculator to stress-test Harmony Biosciences Holdings assumptions and compare it against 35,000+ other stocks.

Main Risks to Consider

While the upside case is compelling, investors should weigh several risks:

Heavy concentration in a single commercial product increases vulnerability to competitive or regulatory setbacks.
Patent litigation and potential generic entry remain ongoing industry concerns, though recent developments have been viewed positively by some analysts.
Management transition, including the recent CFO departure, introduces short-term execution uncertainty.
Broader healthcare-sector volatility and reimbursement pressures could affect adoption rates.

Balanced Verdict

Harmony Biosciences Holdings presents a classic growth-at-a-reasonable-price opportunity. Our models indicate the market has not fully recognized the durability of WAKIX demand or the optionality in the pipeline. At current levels the stock offers substantial upside to fair value with a respectable quality profile. As always, this analysis is educational and not financial advice—individual investors should conduct their own due diligence or consult an advisor. Explore more opportunities with our fair value calculator.

Frequently Asked Questions

Is Harmony Biosciences Holdings undervalued?

Yes, according to our multi-model fair value analysis, HRMY trades at $36.84 against a fair value of $60.3, implying 63.7% upside with a Quality Score of 66/100.

What drives Harmony Biosciences valuation?

Key drivers include robust WAKIX revenue growth, reaffirmed 2026 guidance of $1B–$1.04B, pipeline expansion in sleep and rare diseases, and attractive multiples relative to projected earnings.

What are the main risks for HRMY stock?

Primary risks center on heavy reliance on a single product (WAKIX), potential competition, regulatory hurdles, and recent management changes including the CFO transition.

Sources

Context gathered via live web search while writing this article:

Check the fair value of any stock worldwide
21 valuation models · 35,000+ stocks · evidence-based
Start free →

Not financial advice · No buy/sell recommendations · Past performance is not a guarantee of future results.